Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Food and Drug Administration, GLP-1
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
2d
GLP-1 weight-loss meds might interfere with endoscopy, colonoscopy
Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...
20h
GLP-1 medications, their effect on bariatrics and cautions for people seeking weight loss without surgery
Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...
18h
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
Psychology Today
2d
GLP-1 Agonists May Help Treatment of Mental Illness and Substance Use
Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...
MedPage Today
7d
The Data Are Clear: Patients Regain Weight After Stopping GLP-1 Drugs
To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...
16h
on MSN
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
2d
on MSN
GLP-1 supplements promise to curb cravings and promote weight loss. Experts are skeptical.
Kourtney Kardashian’s vitamin and supplement brand Lemme launched GLP-1 daily capsules in mid-September. For $90 a month, the ...
FierceBiotech
3d
After phase 1 data drop, Metsera allies with Amneal for supply of GLP-1, amylin weight loss candidates
With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback